February 2, 2021 -- Adverum Biotechnologies has published preclinical data on its intravitreal gene therapy candidate ADVM-022 in Translational Vision Science & Technology.
ADVM-022 uses a propriety vector capsid, AAV.7m8, carrying an aflibercept (vascular endothelial growth factor [VEGF] inhibitor) coding sequence under the control of a proprietary expression cassette.
The nonhuman primate data presented in the study represents the longest safety and expression study of the candidate to date, with measurements extended 30 months post-single intravitreal injection. From the study, ADVM-022 appears to be safe and well-tolerated with sustained therapeutic levels of aflibercept expression post intravitreal injection of the product.
ADVM-022 is currently in clinical trials for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The company plans to begin a pivotal trial in mid-2021 for ADVM-022 in wet AMD.
Copyright © 2021 scienceboard.net